Abstract: Genes do not function alone but through complex biological pathways in complex diseases such as Alzheimer's disease (AD). Unravelling these intricate pathways is essential to understanding biological mechanisms of the AD. Based on the integrated pathway analysis database (IPAD), we developed a pathway-based method to detect association with the AD. First, we performed risk associated allele analysis to determine if a major or minor allele is associated with risk. Then we performed pathway-disease association analysis to identify 133 AD-associated pathways. Lastly, we performed pathway-patient association analysis to investigate the patient's association and distribution among the 133 pathways. We found five AD-associated pathways that have the highest association with patients. We present a pathway-based method to detect AD-associated pathways from GWAS data. Our pathway-based analysis not only provides a technique to identify disease-associated pathways, but also help determine the pathwaypatient association.
Introduction
Alzheimer's disease (AD) is the most common form of age-related neurodegenerative dementia and one of the most serious public health issues in the United States. A large number of variants have been studied, however over 50% of the genetic variation remains unexplained (Lambert et al., 2013b) . Many of these variants, aside from APOE, have small effect sizes. Some possible explanations for the source of this missing heritability include rare variants with large effect sizes, epistatic interactions between multiple common alleles, inflated heritability statistics and genetic heterogeneity, among others (Bertram and Tanzi, 2012) .
The AD is characterised by the presence of extracellular plaques formed from the cleaved amyloid precursor protein and intracellular neurofibrillary tangles caused by hyperphosphorylated microtubule-associated protein tau (Arai et al., 2010) . These plaques and tangles are neurotoxic, and result in the progressive loss of neurons and synapses. By the time the disease has progressed to this stage, there is no treatment that can slow or repair these processes. While the hallmarks of the late-stage AD are homogenous, with all patients exhibiting neurotoxic plaques and tangles coupled with cognitive decline, biomarker studies have shown that early-stage AD is heterogeneous. These studies suggest that not all patients arrive at late-stage AD through the same etiologies. Examples of these etiologies include chronic inflammation, altered lipid metabolism, and altered amyloid precursor processing (Fehlbaum-Beurdeley et al., 2010) .
Genome-wide association studies (GWAS) have been used extensively to identify risk loci in many complex diseases, including the AD. For example, Lambert et al. identified 11 new susceptibility loci for Alzheimer's disease by performing a large, twostage meta-analysis of GWAS in 74,046 individuals of European ancestry (Lambert et al., 2013a) . In stage 1, the authors used 4 previously published datasets, which contained 17,008 Alzheimer's disease samples and 37,154 controls. In stage two, they genotyped and investigated the association between 11,632 SNPs and AD in an independent set of 8572 Alzheimer's disease samples and 11,312 controls. They found 19 loci were associated with Alzheimer's disease. Beecham et al. (2014) performed a GWAS for Alzheimer's Disease and related dementias, using known genetic risk loci for AD dementia and 4914 brain autopsies (Beecham et al., 2014) . Twelve of the 22 genetic risk loci for clinically defined AD dementia in their pathologic sample were confirmed (Beecham et al., 2014) . The approach of candidate SNPs or genes analysis in GWAS was used to uncover genetic contributions to complex disease. It is hypothesis-free and virtually would identify all known and unknown genes. However, there are critics of this method:
• low reproducibility
• false positive rates
• insufficient sample size
• limited prior knowledge of association of candidate genes with the AD (Chang et al., 2014) .
Moreover, the biological mechanisms identified with single marker level in AD GWAS remain controversial (Lee and Song, 2015) . Therefore, the goal of this study was to use genotype data to perform pathway analysis on a cohort of late-stage AD patients. This allowed us to bin patients into their respective etiologies through which they may have arrived at the late-stage AD. This accomplishes two things. Firstly, treatments that target these up-stream etiologies may be designed and more effectively tested in cohorts of patients that can be expected to respond to them. Secondly, this method is a proof of concept for studying the upstream pathways that may lead to an eventual AD diagnosis which would be beneficial for earlier detection and possible treatment.
Materials and methods

Samples and data collection
We conducted a case-control study for SNP array analysis (n = 166 AD and n = 134 Normal Control (NC)). Normal control subjects were matched to AD patients on age, sex, education and etc. (Table 1) . Published Texas Alzheimer's Research and Care Consortium (TARCC) methodologies are described elsewhere (Waring et al., 2008) . Criteria for categorising subjects as a probable AD, mild cognitive impairment (MCI) or normal control (NC) are based on neurocognitive evaluations, family and/or caregiver interviews and medical history. NC must have normal psychometric test scores and a clinical dementia rating (CDR) score of 0. MCI subjects are classified based on the Mayo Clinic Alzheimer's Disease Research Criteria (Petersen, 2004) . Patients are characterised as probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) criteria (McKhann et al., 1984) . Each participating site operates under Institutional Review Board approval, and written informed consent is obtained from every participant. The TARCC cohort was genotyped using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA), which includes 906,600 SNP markers. Locally developed Java programs (collectively termed MaCHTools) were used to perform critical data quality checking/filtering, imputation analysis, and data restructuring to affect overall computational performance. Participants were excluded from analysis if the recorded sex did not agree with chromosome markers or if >5% of the markers did not successfully run. Markers were excluded from analysis if 5% of samples were missing, if they were monomorphic (threshold set at 0.01) or if they were out of Hardy-Weinberg Equilibrium (threshold set at 0.000001). In addition, genotype calls for important markers were manually checked independent of phenotype and recalled as necessary in order to account for obvious atypical hybridisation intensities (such as discussed in Didion et al., 2012) . This checking was conducted on the entire sample, without knowledge of diagnostic status or phenotype. Results were limited to loci with a minor allele frequency greater than 5%.
Risky-associated allele analysis
Risk-associated alleles are defined as the alleles most strongly associated with disease.
To detect risk alleles, we use proportional test for independence to determine whether allele is associated to AD, comparing observed data with data we would expect to obtain according to a null hypothesis that the difference between the expected frequencies and observed frequencies of each allele is equal to zero. Figure 1 shows the process of risk-associated allele analysis. First, we calculate the genotype counts for each SNP. Then, we obtained the observed allele counts and expected allele counts followed by calculating the p-value of the proportional test for each allele respectively using the prop.test function in R. Lastly, the allele with minimum p-value is chosen as the risk allele for each SNP.
Pathway-disease association analysis
Pathway-disease association analysis is performed to identify pathways that are enriched for disease, and, unlike traditional pathway analysis, it is based on risk allele numbers, not gene number or SNP number. First we calculate the risk allele number for each SNP across AD patients and normal controls. Suppose we have three types of genotypes: Heterozygous Aa, Homozygous AA, and Homozygous aa. If A is identified as risk allele, then the risk allele numbers are 1, 2, and 0 for Aa, AA, and aa, respectively. In each pathway, we use the proportion test to compare the proportion of the number of risk alleles in the AD to the proportion of the number of risk alleles in normal controls and test if the proportion of the number of risk alleles in the AD is greater than the proportion of the number of risk alleles in normal controls. The pathway where the proportion of number of risk alleles in the AD is greater than the proportion of the number of risk alleles in normal controls is called AD-enriched or AD-associated pathway. The analysis is based on the hypothesis for a proportion test that the difference between the expected frequencies and observed frequencies of each allele is equal to zero.
Pathway-patient association analysis
Pathway-patient association analysis is performed to identify pathways that are enriched for each individual based on the number of risk alleles. First, we obtain the risk allele counts for pathway i and individual j, then we sum up the risk alleles number by the patient and by pathway, respectively, and obtain L j and M i . Next, we sum up the M i and obtain the total number of risk alleles for all individuals and pathways. The contingency table for Fisher test is showed in Figure 3 . We used the fisher.test function in R for calculating the p-value of the Fisher test.
Pathway analysis
Interpretation of biological pathways was conducted with the database we developed: Integrated Pathway Analysis Database (IPAD) (http://bioinfo.hsc.unt.edu/ipad/) (Zhang and Drabier, 2012) .
Figure 2 Proportion test of risk allele count
The analysis is based on the hypothesis for a proportion test that the proportion of the number of risk alleles in the AD is greater than the proportion of the number of risk alleles in normal controls. 
Results
The schema of methods in this paper is shown in Figure 4 . First, SNP array profiles were collected from 300 individuals (166 ADs and 134 normal control, Table 1 ). We carried out the quality control, array normalisation, and array genotyping using the method described in the samples and data collection section. After these above steps, we obtained 2418 SNPs with a threshold of p-value < 0.01, which were mapped to 257 KEGG pathways by using the IPAD (Zhang and Drabier, 2012) . First, SNP array with genotype and phenotype were prepared and subjected to quality checking/filtering and preliminary analysis. Next, a risky-associated allele analysis was performed to detect the risky alleles. Next, pathway-disease association analysis was performed to detect 133 AD-associated pathways. Then, pathway-disease association analysis was performed to identify 5 out of 133 AD-associated pathways as ADassociated and patient-associated pathways. Last, a prediction model was built to measure the prediction performance of the five AD-associated and patient-associated pathway.
First, we calculated the p-value of proportion test for the two alleles in each SNP and chose the allele with minimum p-value as risk allele. We performed the pathway-disease association analysis on basis of risk allele counts. The top 133 AD-associated pathways were identified after we calculated the q-value of proportion test for the AD and normal controls and chose q-value < 0.01 as threshold (Additional file 1).
Pathway analysis shows the pathways linked with the AD are Parkinson's disease, signalling, cancer, Alzheimer's disease, and inflammation and infection. The first AD-associated pathway is Protein processing in endoplasmic reticulum pathway. It contains 44 SNPs from 6 genes including PARK2 and EIF2AK3. The risk allele number is 13143 and 11894 in the AD and normal controls, respectively. The Parkinson's disease pathway and Ubiquitin-mediated proteolysis are also linked with the AD by the PARK2.
We then performed the pathway-patient association analysis. We found 5 out of 133 AD-associated pathways are also linked with patients (Table 2, Figure 5 ). The number of linked patients are 9, 14, 9, 2, and 2, respectively, for Protein processing in endoplasmic reticulum pathway, Parkinson's disease pathway, Ubiquitin mediated proteolysis pathway, Non-small cell lung cancer pathway and Systemic lupus erythematosus pathway. In the detailed pathway-patient association matrix, we can identify patientassociated pathways by 'querying by Patient' and pathway-associated patients by 'querying by pathway'.
Lastly, we evaluated the top five AD-associated and patient-associated pathways' prediction performance by predicting the AD status for the individuals we found associated with the top five pathways. We achieved an AUC of 0.935, which is improved from the AUC of 0.6 which we achieved when we used the top five pathways to predict all individuals. The other four measurements: Precision, Accuracy, Sensitivity, and Specificity were also improved (Table 3 , Precision = 80.95%, Accuracy = 84.85%, Sensitivity = 94.4%, Specificity = 73.33%). The five AD-associated and patient-associated pathways are linked with the AD. Each block shows a pathway with associated gene number and SNP number. The digital numbers in the middle of connection lines between five pathways and AD are the number of linked patients.
Table 2
Top 5 AD-associated and patient-associated pathways Table 2 Top 5 AD-associated and patient-associated pathways (continued) 
Discussion
We describe here a pathway analysis method to identify AD-associated pathways from GWAS. First, we performed the risk-associated allele analysis. Then we performed pathway-disease association analysis based on risk alleles number and identified 133 AD-associated pathways. Lastly, we performed pathway-patient association analysis and found most patients are linked with 5 AD-associated pathways we identified. The 5 AD-associated and patient-associated pathways are Protein processing in endoplasmic reticulum (6genes, 44 SNPs, 9 associated patients), Parkinson's disease (4 genes, 34 SNPs, 14 associated patients), Ubiquitin mediated proteolysis (6genes, 40 SNPs, 9 associated patients), Non-small cell lung cancer (5 genes, 23 SNPs, 2 associated patients), and Systemic lupus erythematosus (3genes, 10 SNPs, 2 associated patients). Disorders in protein conformation effecting ER processing are the underlying basis for a wide range of sporadic and inherited diseases including AD (Aridor and Balch, 1999) . Amyloid precursor protein (APP) is an integral membrane protein and plays a key role in the pathogenesis of AD, from which a major pathological hallmark of Alzheimer's disease (AD), Beta-amyloid (Aβ), is derived through sequential cleavage by β-secretase and γ-secretase enzymes (Jung et al., 2015) . Recent studies believe that chronic ER stress and abnormal regulation of UPS contribute to the progression of the AD (Jung et al., 2015) . Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome-dependent protein degradation. Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that results primarily from the death of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc). The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Since Alzheimer's disease (AD) is a progressive neurodegenerative disorder and ageing is accompanied by changes in cellular protein homeostasis and an increasing demand for protein degradation, protein folding, misfolding, sorting, and degradation is linked to AD pathogenesis (Morawe et al., 2012) . The last two pathways: Non-small cell lung cancer and Systemic lupus erythematosus suggest that there may exist a common or inverse biological mechanism between AD and cancer or autoimmune disease. For example, Maria et al. demonstrated that cell regulation mechanisms are disrupted with augmentation of cell survival and/or proliferation in cancer but conversely AD is associated with increased neuronal death, either caused by, or concomitant with, beta amyloid (Aβ) and tau deposition (Behrens et al., 2009) . Systemic lupus erythematosus (SLE) is an autoimmune disease. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Patients with SLE can experience acute neurological events such as seizures, cerebrovascular accidents, and delirium, psychiatric conditions including depression, anxiety, and psychosis, as well as memory loss and general cognitive decline, which are similar to patients with the AD (Stock et al., 2013) .
Our results suggest that multiple pathways might work together to contribute to the development of AD. Previous research shows that that genes do not function alone but through complex biological pathways. In the AD, many pathways might work together at different levels -from organs to cells to genes. For example, signalling pathways play an integral role in mediating signals for cell growth, survival, cell-cycle progression, differentiation, transcription, translation, and glucose metabolism. Protein folding, sorting and degradation pathways serve as a protein-folding factory and are crucial for protein function and stability (Araki and Nagata, 2012) . When some biological pathways do not work properly, the result can lead to complex disease.
Our results also show that focusing on patients-specific, disease-associated pathways can achieve better prediction performance. Complex human diseases such as the AD should be investigated and treated differently in each individual case. The development of the AD is a complex physiological process guided by a sequential chain of molecular changes within the cell. These changes may originate from different molecular events, largely dealing with the activation of the intracellular signalling pathways. Normally, signalling pathways regulate all of the transitions of the cell life cycle including cell growth, division, differentiation, migration, and cell death. In the AD, the activity of intracellular signalling pathways is largely misbalanced and the effects of the different individual AD diagnoses may be due to dysregulation of very different intracellular signalling pathways. Therefore, medical treatment of AD requires an understanding of the molecular grounds of dysregulation, which may provide clues for finding proper therapeutics for the treatment of individual ADs.
Another interesting finding is the gene PARK2, which exists in the top 3 pathways. The parkin gene, an E2-dependent ubiquitin protein ligase, was previously found responsible for a familial form of Parkinson's disease (Bandres-Ciga et al., 2016; Zanellati et al., 2015) . Along with Parkinsonism forms, PARK2 gene has also been found linked to other human pathologies, such as Alzheimer disease (Burns et al., 2009 ). This may be due to comorbid AD and PD or some common mechanisms in "upstream initiation" of AD and PD. Recently, Greene et al. used tissue-specific networks to analyse gene-disease associations and found that Parkinson's disease was strongly connected to many other diseases including brain disease, likely through the ubiquitin-protein ligase gene PARK2 (Greene et al., 2015) .
Science-Business eXchange reported Eukaryotic translation factor 2α kinase 3 (EIF2AK3) as a biomarker for the AD in 2013. Protein synthesis repressed by phosphorylation of eukaryotic initiation factor 2 α-subunit (eIF2α) plays important role in the expression of long-lasting synaptic plasticity and long-term memory requires. Ma et al. found that phosphorylation of eukaryotic initiation factor 2α was greater in brain samples from patients or mouse models of the AD than that in healthy controls (Ma et al., 2013) . They also tested whether suppressing eIF2α kinases could alleviate synaptic plasticity and memory deficits in Alzheimer's disease model mice. They found hippocampal-specific depletion of either eIF2α kinase PERK or another eIF2α kinase GCN2 improved learning and memory performance and prevented enhanced phosphorylation of eIF2α and deficits in protein synthesis, synaptic plasticity and spatial memory in mouse models of the AD (Ma et al., 2013) . Their findings implicated aberrant eIF2α phosphorylation as a molecular mechanism underlying Alzheimer's disease-related synaptic pathophysiology and memory dysfunction and suggested that eIF2α kinase PERK and another eIF2α kinase are potential therapeutic targets for treatment of individuals with Alzheimer's disease (Ma et al., 2013) .
Conclusion
We developed a pathway-based method to detect association with the AD. The method contains three steps: risk-association allele analysis, pathway-disease association analysis, and pathway-patient association analysis. Using the pathway-based association analysis method, we identified 133 AD-associated pathways. Among them 5 pathways are also associated with patients:
• protein processing in endoplasmic reticulum
• ubiquitin mediated proteolysis
• non-small cell lung cancer
• systemic lupus erythematosus.
Unravelling these intricate pathways is essential to understanding biological mechanisms in the AD.
We believe that our method can lead to the identification of potential pathways that serve as targets for treatment of Alzheimer's diseases.
